drugset
drugset / Trial / NCT04931524

A Study to Assess the Absorption, Metabolism and Excretion of [14C]-ANG-3777

NCT04931524 ↗

Phase 1 Unknown 6 enrolled Angion Biomedica Corp Quotient Sciences · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the mass balance recovery and metabolic profiling and identification of 14C-ANG-3777 administered as a single IV dose.

Timeline

Start
2021-05-21
Primary completion
2021-06
Completion
2021-06

Drugs

EvaluationDrugModalityDoseRoute
Subject TEREVALEFIM Small molecule 5.2 mbq Intravenous
Subject TEREVALEFIM Small molecule 240 mg Intravenous

Indications

No indication recorded.